RETRACTED: CSF p-tau as a potential cognition impairment biomarker in ALS
BackgroundCerebrospinal fluid (CSF) and serum tau (t-tau, p-tau) are potential biomarkers for neurodegeneration in Alzheimer disease (AD), but their role in amyotrophic lateral sclerosis (ALS) is unclear.ObjectivesThe aim of our study was to evaluate CSF and serum p-tau and t-tau in patients with AL...
Main Authors: | Zhongying Gong, Lina Gao, Yi Lu, Zhiyun Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.991143/full |
Similar Items
-
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
by: Juan Lantero‐Rodriguez, et al.
Published: (2021-11-01) -
P-tau217 as a Reliable Blood-Based Marker of Alzheimer’s Disease
by: Roy Lai, et al.
Published: (2024-08-01) -
A novel monoclonal antibody generated by immunization with granular tau oligomers binds to tau aggregates at 423-430 amino acid sequence
by: Yoshiyuki Soeda, et al.
Published: (2024-07-01) -
The neutrophil to lymphocyte ratio associates with markers of Alzheimer’s disease pathology in cognitively unimpaired elderly people
by: Tovia Jacobs, et al.
Published: (2024-05-01) -
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
by: Juan Lantero-Rodriguez, et al.
Published: (2024-02-01)